New tumor models provide insights into deadly sarcomas
Sarcomas are highly metastatic soft tissue and bone cancers and are often difficult to treat. Scientists have had trouble ...
Targeted Oncology9d
FDA Grants Elraglusib Orphan Drug Designation in Soft Tissue Sarcoma
The FDA granted orphan drug designation for elraglusib, a novel drug for treating advanced soft tissue sarcoma.
Pharmaceutical Technology12d
Pamiparib by BeiGene for Endometrial Cancer: Likelihood of Approval
Pamiparib (Baihuize) is an anti-neoplastic agent. It is formulated as capsules for oral route of administration. Baihuize is indicated for the treatment of patients with germline BRCA ...
Pharmaceutical Technology12d
Pamiparib by BeiGene for Ovarian Cancer: Likelihood of Approval
Pamiparib is under clinical development by BeiGene and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II drugs for Ovarian Cancer have a 26% phase transition success rate ...
The American Journal of Managed Care9d
Elraglusib Granted FDA Orphan Drug Status in Soft Tissue Sarcoma
The FDA granted orphan drug designation for elraglusib, a novel drug for treating advanced soft tissue sarcoma.